Literature DB >> 8858475

Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in western Europe and in the USA. The Alexander Project Collaborative Group.

S L Berk1, J H Kalbfleisch.   

Abstract

Eight hundred and eighteen Moraxella catarrhalis strains, isolated in 1992 and 1993 at 15 centres in Western Europe and the USA were tested for beta-lactamase production and resistance to 15 antibiotics. The proportion of beta-lactamase producing strains in Europe rose significantly from 70% in 1992 to 82% in 1993, whilst in the USA the increase (85-92%) was not significant. Penicillin and amoxycillin resistance was more prevalent in the USA than in Europe. All penicillin-resistant strains isolated in the USA exhibited beta-lactamase activity, whilst 8% of beta-lactamase-negative strains isolated in Europe were also penicillin resistant. All but three isolates were sensitive to cefaclor, cefuroxime, cefixime and ceftriaxone, all but one were sensitive to ofloxacin and all were sensitive to ciprofloxacin and amoxycillin cluvulanate. Resistance to erythromycin was not encountered, although 19 strains had MICs > or = 0.5 mg/L. Of these, 15 came from European centres. Almost all strains were highly susceptible to clarithromycin, azithromycin, doxycycline and co-trimoxazole.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858475     DOI: 10.1093/jac/38.suppl_a.85

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.

Authors:  Franz-Josef Schmitz; Andreas Beeck; Mirella Perdikouli; Mechthild Boos; Susanne Mayer; Sybille Scheuring; Karl Köhrer; Jan Verhoef; Ad C Fluit
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

3.  The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance.

Authors:  D J Austin; K G Kristinsson; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

4.  Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models.

Authors:  D J Austin; R M Anderson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model.

Authors:  Dai-Fang Liu; John C McMichael; Steven M Baker
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

7.  Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.

Authors:  G A Pankuch; D B Hoellman; G Lin; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 8.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.

Authors:  Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-05-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.